Citations (98)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Teklie Mengie Ayele, Zelalem Tilahun Muche, Awgichew Behaile Teklemariam, Achenef Bogale Kassie & Endeshaw Chekol Abebe. (2022) Role of JAK2/STAT3 Signaling Pathway in the Tumorigenesis, Chemotherapy Resistance, and Treatment of Solid Tumors: A Systemic Review. Journal of Inflammation Research 15, pages 1349-1364.
Read now
Read now
Changhong Yin, Claudio Sandoval & Gyeong-Hun Baeg. (2015) Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia. Leukemia & Lymphoma 56:5, pages 1502-1506.
Read now
Read now
Christian Riehle, Adam R. Wende, Yi Zhu, Karen J. Oliveira, Renata O. Pereira, Bharat P. Jaishy, Jack Bevins, Steven Valdez, Junghyun Noh, Bum Jun Kim, Annie Bello Moreira, Eric T. Weatherford, Rajkumar Manivel, Tenley A. Rawlings, Monika Rech, Morris F. White & E. Dale Abel. (2014) Insulin Receptor Substrates Are Essential for the Bioenergetic and Hypertrophic Response of the Heart to Exercise Training. Molecular and Cellular Biology 34:18, pages 3450-3460.
Read now
Read now
Hiu Kiu & Sandra E. Nicholson. (2012) Biology and significance of the JAK/STAT signalling pathways. Growth Factors 30:2, pages 88-106.
Read now
Read now
Scott A. Robertson, Rositsa I. Koleva, Lawrence S. Argetsinger, Christin Carter-Su, Jarrod A. Marto, Edward P. Feener & Martin G. Myers$suffix/text()$suffix/text(). (2009) Regulation of Jak2 Function by Phosphorylation of Tyr317 and Tyr637 during Cytokine Signaling. Molecular and Cellular Biology 29:12, pages 3367-3378.
Read now
Read now
Hanyin Cheng, Jeremy A. Ross, Jeffrey A. Frost & Robert A. Kirken. (2008) Phosphorylation of Human Jak3 at Tyrosines 904 and 939 Positively Regulates Its Activity. Molecular and Cellular Biology 28:7, pages 2271-2282.
Read now
Read now
Megumi Funakoshi-Tago, Stéphane Pelletier, Hiroshi Moritake, Evan Parganas & James N. Ihle. (2008) Jak2 FERM Domain Interaction with the Erythropoietin Receptor Regulates Jak2 Kinase Activity. Molecular and Cellular Biology 28:5, pages 1792-1801.
Read now
Read now
Anna M. Mazurkiewicz-Munoz, Lawrence S. Argetsinger, Jean-Louis K. Kouadio, Allan Stensballe, Ole N. Jensen, Joel M. Cline & Christin Carter-Su. (2006) Phosphorylation of JAK2 at Serine 523: a Negative Regulator of JAK2 That Is Stimulated by GrowthHormone and Epidermal Growth Factor. Molecular and Cellular Biology 26:11, pages 4052-4062.
Read now
Read now
Ryoko Ishida-Takahashi, Felicia Rosario, Yusong Gong, Keely Kopp, Zlatina Stancheva, Xiaohong Chen, Edward P. Feener & Martin G. Myers$suffix/text()$suffix/text(). (2006) Phosphorylation of Jak2 on Ser523 InhibitsJak2-Dependent Leptin ReceptorSignaling. Molecular and Cellular Biology 26:11, pages 4063-4073.
Read now
Read now
Edward P. Feener, Felicia Rosario, Sarah L. Dunn, Zlatina Stancheva & Martin G. Myers$suffix/text()$suffix/text(). (2004) Tyrosine Phosphorylation of Jak2 in the JH2 Domain Inhibits Cytokine Signaling. Molecular and Cellular Biology 24:11, pages 4968-4978.
Read now
Read now
Articles from other publishers (88)
Iris E. Glykofridis, Alex A. Henneman, Jesper A. Balk, Richard Goeij-de Haas, Denise Westland, Sander R. Piersma, Jaco C. Knol, Thang V. Pham, Michiel Boekhout, Fried J.T. Zwartkruis, Rob M.F. Wolthuis & Connie R. Jimenez. (2022) Phosphoproteomic Analysis of FLCN Inactivation Highlights Differential Kinase Pathways and Regulatory TFEB Phosphoserines. Molecular & Cellular Proteomics 21:9, pages 100263.
Crossref
Crossref
Mathilde Regimbeau, Romain Mary, François Hermetet & François Girodon. (2022) Genetic Background of Polycythemia Vera. Genes 13:4, pages 637.
Crossref
Crossref
Michael Stephan Bader & Sara Christina Meyer. (2022) JAK2 in Myeloproliferative Neoplasms: Still a Protagonist. Pharmaceuticals 15:2, pages 160.
Crossref
Crossref
Panhong Gou, Wenchao Zhang & Stephane Giraudier. (2022) Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms. International Journal of Molecular Sciences 23:3, pages 1013.
Crossref
Crossref
Sarrah L. Hasanali, Daley S. Morera, Ronny R. Racine, Martin Hennig, Santu Ghosh, Luis E. Lopez, Marie C. Hupe, Diogo O. Escudero, Jiaojiao Wang, Huabin Zhu, Semih Sarcan, Ijeoma Azih, Michael Zhou, Andre R. Jordan, Martha K. Terris, Markus A. Kuczyk, Axel S. Merseburger & Vinata B. Lokeshwar. (2021) HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer. Clinical Cancer Research 27:15, pages 4410-4421.
Crossref
Crossref
Salma Merchant. 2021. Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A. Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A
117
162
.
Ger J. Strous, Ana Da Silva Almeida, Joyce Putters, Julia Schantl, Magdalena Sedek, Johan A. Slotman, Tobias Nespital, Gerco C. Hassink & Jan A. Mol. (2020) Growth Hormone Receptor Regulation in Cancer and Chronic Diseases. Frontiers in Endocrinology 11.
Crossref
Crossref
Friederike Pastore, Aishwarya Krishnan, Henrik M. Hammarén, Olli SilvennoinenBenedict YanRoss L. Levine. (2020) JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F− MPNs. Blood Advances 4:18, pages 4554-4559.
Crossref
Crossref
Chalita Washington, Rachel Chernet, Rewatee H. Gokhale, Yesenia Martino-Cortez, Hsiu-Yu Liu, Ashley M. Rosenberg, Sivan Shahar & Cathie M. Pfleger. (2020) A conserved, N-terminal tyrosine signal directs Ras for inhibition by Rabex-5. PLOS Genetics 16:6, pages e1008715.
Crossref
Crossref
Regina Gratz, Tzvetina Brumbarova, Rumen Ivanov, Ksenia Trofimov, Laura Tünnermann, Rocio Ochoa‐Fernandez, Tim Blomeier, Johannes Meiser, Stefanie Weidtkamp‐Peters, Matias D. Zurbriggen & Petra Bauer. (2019)
Phospho‐mutant activity assays provide evidence for alternative phospho‐regulation pathways of the transcription factor
FER‐LIKE IRON DEFICIENCY‐INDUCED TRANSCRIPTION FACTOR
. New Phytologist 225:1, pages 250-267.
Crossref
Crossref
Henrik M. Hammarén, Anniina T. Virtanen, Juuli Raivola & Olli Silvennoinen. (2019) The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine 118, pages 48-63.
Crossref
Crossref
Caroline E. Nunes-Xavier, Janire Mingo, José I. López & Rafael Pulido. (2019) The role of protein tyrosine phosphatases in prostate cancer biology. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1866:1, pages 102-113.
Crossref
Crossref
Claire Speirs, Jamie J.L. Williams, Kirsten Riches, Ian P. Salt & Timothy M. Palmer. (2018) Linking energy sensing to suppression of JAK-STAT signalling: A potential route for repurposing AMPK activators?. Pharmacological Research 128, pages 88-100.
Crossref
Crossref
Stevan R. Hubbard. (2018) Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase. Frontiers in Endocrinology 8.
Crossref
Crossref
John G. Noel, Benjamin J. Ramser, Jose A. Cancelas, Francis X. McCormack & Jason C. Gardner. (2017) Thermal injury of the skin induces G-CSF-dependent attenuation of EPO-mediated STAT signaling and erythroid differentiation arrest in mice. Experimental Hematology 56, pages 16-30.
Crossref
Crossref
Ichiro Kawashima & Keita Kirito. (2016) Metformin inhibits JAK2V617F activity in MPN cells by activating AMPK and PP2A complexes containing the B56α subunit. Experimental Hematology 44:12, pages 1156-1165.e4.
Crossref
Crossref
Zaheer Ul-Haq, Sehrish Naz & M. Ahmed Mesaik. (2016) Interleukin-4 receptor signaling and its binding mechanism: A therapeutic insight from inhibitors tool box. Cytokine & Growth Factor Reviews 32, pages 3-15.
Crossref
Crossref
Robert RoskoskiJr.Jr.. (2016) Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacological Research 111, pages 784-803.
Crossref
Crossref
A M Roncero, P López-Nieva, M A Cobos-Fernández, M Villa-Morales, L González-Sánchez, J L López-Lorenzo, P Llamas, C Ayuso, S M Rodríguez-Pinilla, M C Arriba, M A Piris, P Fernández-Navarro, A F Fernández, M F Fraga, J Santos & J Fernández-Piqueras. (2015) Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development. Leukemia 30:1, pages 94-103.
Crossref
Crossref
Burak Bahar, Kevin Barton & Ameet R. Kini. (2016) The role of the Exon 13 G571S JAK2 mutation in myeloproliferative neoplasms. Leukemia Research Reports 6, pages 27-28.
Crossref
Crossref
Małgorzata Szewczuk. (2015)
Association of a genetic marker at the bovine Janus kinase 2 locus (
JAK2
/
Rsa
I) with milk production traits of four cattle breeds
. Journal of Dairy Research 82:3, pages 287-292.
Crossref
Crossref
Sara C. Meyer, Matthew D. Keller, Sophia Chiu, Priya Koppikar, Olga A. Guryanova, Franck Rapaport, Ke Xu, Katia Manova, Dmitry Pankov, Richard J. O’Reilly, Maria Kleppe, Anna Sophia McKenney, Alan H. Shih, Kaitlyn Shank, Jihae Ahn, Eftymia Papalexi, Barbara Spitzer, Nick Socci, Agnes Viale, Emeline Mandon, Nicolas Ebel, Rita Andraos, Joëlle Rubert, Ernesta Dammassa, Vincent Romanet, Arno Dölemeyer, Michael Zender, Melanie Heinlein, Raajit Rampal, Rona Singer Weinberg, Ronald Hoffman, William R. Sellers, Francesco Hofmann, Masato Murakami, Fabienne Baffert, Christoph Gaul, Thomas Radimerski & Ross L. Levine. (2015) CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell 28:1, pages 15-28.
Crossref
Crossref
A A Sahasrabuddhe, X Chen, F Chung, T Velusamy, M S Lim & K S J Elenitoba-Johnson. (2014) Oncogenic Y641 mutations in EZH2 prevent Jak2/β-TrCP-mediated degradation. Oncogene 34:4, pages 445-454.
Crossref
Crossref
Jorge Martín-Pérez, José Manuel García-Martínez, María Pilar Sánchez-Bailón, Víctor Mayoral-Varo & Annarica Calcabrini. 2015. Recent Advances in Prolactin Research. Recent Advances in Prolactin Research
163
188
.
Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola & Leila N. Varghese. (2014) The molecular regulation of Janus kinase (JAK) activation. Biochemical Journal 462:1, pages 1-13.
Crossref
Crossref
Yibing Shan, Kavitha Gnanasambandan, Daniela Ungureanu, Eric T Kim, Henrik Hammarén, Kazuo Yamashita, Olli Silvennoinen, David E Shaw & Stevan R Hubbard. (2014) Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase. Nature Structural & Molecular Biology 21:7, pages 579-584.
Crossref
Crossref
Leila N. Varghese, Daniela Ungureanu, Nicholas P. D. Liau, Samuel N. Young, Artem Laktyushin, Henrik Hammaren, Isabelle S. Lucet, Nicos A. Nicola, Olli Silvennoinen, Jeffrey J. Babon & James M. Murphy. (2014) Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses. Biochemical Journal 458:2, pages 395-405.
Crossref
Crossref
S. Leah EtheridgeMegan E. CosgroveVeena SangkhaeLana M. CorboMichelle E. RohMarkus A. Seeliger, Edward L. Chan & Ian S. Hitchcock. (2014) A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis. Blood 123:7, pages 1059-1068.
Crossref
Crossref
Anne Trécul, Franck Morceau, Anthoula Gaigneaux, Marion Orsini, Sébastien Chateauvieux, Cindy Grandjenette, Mario Dicato & Marc Diederich. (2013) Polyphenol tri-vanillic ester 13c inhibits P-JAK2V617F and Bcr–Abl oncokinase expression in correlation with STAT3/STAT5 inactivation and apoptosis induction in human leukemia cells. Cancer Letters 340:1, pages 30-42.
Crossref
Crossref
Nicole M. Anderson, Mojib Javadi, Elizabeth Berndl, Zorana Berberovic, Monica L. Bailey, Kai Huang, Ann M. Flenniken, Lucy R. Osborne, S. Lee Adamson, Janet Rossant, Christin Carter-Su, Chen Wang, Kelly M. McNagny, Robert F. Paulson, Mark D. Minden, William L. Stanford & Dwayne L. Barber. (2013) Enu Mutagenesis Identifies a Novel Platelet Phenotype in a Loss-Of-Function Jak2 Allele. PLoS ONE 8:9, pages e75472.
Crossref
Crossref
Stefan N. Constantinescu, Emilie Leroy, Vitalina Gryshkova, Christian Pecquet & Alexandra Dusa. (2013) Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers. Biochemical Society Transactions 41:4, pages 1048-1054.
Crossref
Crossref
Olli Silvennoinen, Daniela Ungureanu, Yashavanthi Niranjan, Henrik Hammaren, Rajintha BandaranayakeStevan R. Hubbard. (2013) New insights into the structure and function of the pseudokinase domain in JAK2. Biochemical Society Transactions 41:4, pages 1002-1007.
Crossref
Crossref
Annika Nerstedt, Emmelie Cansby, Manoj Amrutkar, Ulf Smith & Margit Mahlapuu. (2013) Pharmacological activation of AMPK suppresses inflammatory response evoked by IL-6 signalling in mouse liver and in human hepatocytes. Molecular and Cellular Endocrinology 375:1-2, pages 68-78.
Crossref
Crossref
Xiuting Chen, Zhe Ying, Xi Lin, Huanxin Lin, Jueheng Wu, Mengfeng Li & Libing Song. (2013) Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. Journal of Clinical Investigation 123:6, pages 2576-2589.
Crossref
Crossref
W Vainchenker & S N Constantinescu. (2012) JAK/STAT signaling in hematological malignancies. Oncogene 32:21, pages 2601-2613.
Crossref
Crossref
Eugenio J. Abente, Stanislav V. Sosnovtsev, Carlos Sandoval-Jaime, Gabriel I. Parra, Karin Bok & Kim Y. Green. (2013) The Feline Calicivirus Leader of the Capsid Protein Is Associated with Cytopathic Effect. Journal of Virology 87:6, pages 3003-3017.
Crossref
Crossref
Jeremy A. Ross, Georgialina Rodriguez & Robert A. Kirken. 2013. JAK-STAT Signalling. JAK-STAT Signalling
3
20
.
Lindsay M. LaFave & Ross L. Levine. (2012) JAK2 the future: therapeutic strategies for JAK-dependent malignancies. Trends in Pharmacological Sciences 33:11, pages 574-582.
Crossref
Crossref
Irina G Luzina, Achsah D Keegan, Nicola M Heller, Graham A W Rook, Terez Shea-Donohue & Sergei P Atamas. (2012) Regulation of inflammation by interleukin-4: a review of “alternatives”. Journal of Leukocyte Biology 92:4, pages 753-764.
Crossref
Crossref
Dongqing Yan, Robert E. Hutchison & Golam Mohi. (2012) Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice. Blood 120:9, pages 1888-1898.
Crossref
Crossref
Rajintha M Bandaranayake, Daniela Ungureanu, Yibing Shan, David E Shaw, Olli Silvennoinen & Stevan R Hubbard. (2012) Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nature Structural & Molecular Biology 19:8, pages 754-759.
Crossref
Crossref
Rita Andraos, Zhiyan Qian, Débora Bonenfant, Joëlle Rubert, Eric Vangrevelinghe, Clemens Scheufler, Fanny Marque, Catherine H. Régnier, Alain De Pover, Hugues Ryckelynck, Neha Bhagwat, Priya Koppikar, Aviva Goel, Lorenza Wyder, Gisele Tavares, Fabienne Baffert, Carole Pissot-Soldermann, Paul W. Manley, Christoph Gaul, Hans Voshol, Ross L. Levine, William R. Sellers, Francesco Hofmann & Thomas Radimerski. (2012) Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent. Cancer Discovery 2:6, pages 512-523.
Crossref
Crossref
William H. Lagarde, Amanda J. Blackwelder, John T. Minges, Andrew T. Hnat, Frank S. French & Elizabeth M. Wilson. (2012) Androgen Receptor Exon 1 Mutation Causes Androgen Insensitivity by Creating Phosphorylation Site and Inhibiting Melanoma Antigen-A11 Activation of NH2- and Carboxyl-terminal Interaction-dependent Transactivation. Journal of Biological Chemistry 287:14, pages 10905-10915.
Crossref
Crossref
Claude Haan, Daniela Ungureanu, Tuija Pekkala, Olli Silvennoinen & Serge Haan. 2012. Jak-Stat Signaling : From Basics to Disease. Jak-Stat Signaling : From Basics to Disease
5
25
.
S Hart, K C Goh, V Novotny-Diermayr, C Y Hu, H Hentze, Y C Tan, B Madan, C Amalini, Y K Loh, L C Ong, A D William, A Lee, A Poulsen, R Jayaraman, K H Ong, K Ethirajulu, B W Dymock & J W Wood. (2011) SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 25:11, pages 1751-1759.
Crossref
Crossref
Jacqueline Sayyah, Kavitha Gnanasambandan, Sushama Kamarajugadda, Shigeharu Tsuda, Jennifer Caldwell-Busby & Peter P. Sayeski. (2011) Phosphorylation of Y372 is critical for Jak2 tyrosine kinase activation. Cellular Signalling 23:11, pages 1806-1815.
Crossref
Crossref
Daniela Ungureanu, Jinhua Wu, Tuija Pekkala, Yashavanthi Niranjan, Clifford Young, Ole N Jensen, Chong-Feng Xu, Thomas A Neubert, Radek C Skoda, Stevan R Hubbard & Olli Silvennoinen. (2011) The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nature Structural & Molecular Biology 18:9, pages 971-976.
Crossref
Crossref
Gary B. Smejkal, Chiara Rivas-Morello, Jae-Hyung Robert Chang, Emily Freeman, Alexander J. Trachtenberg, Alexander Lazarev, Alexander R. Ivanov & Winston P. Kuo. (2011) Thermal stabilization of tissues and the preservation of protein phosphorylation states for two-dimensional gel electrophoresis. ELECTROPHORESIS 32:16, pages 2206-2215.
Crossref
Crossref
Arturo Sanz, Daniela Ungureanu, Tuija Pekkala, Rob Ruijtenbeek, Ivo P. Touw, Riet Hilhorst & Olli Silvennoinen. (2011) Analysis of Jak2 Catalytic Function by Peptide Microarrays: The Role of the JH2 Domain and V617F Mutation. PLoS ONE 6:4, pages e18522.
Crossref
Crossref
A Samanta, B Perazzona, S Chakraborty, X Sun, H Modi, R Bhatia, W Priebe & R Arlinghaus. (2010) Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia. Leukemia 25:3, pages 463-472.
Crossref
Crossref
Mandar V. Kulkarni, M. Cristina Tettamanzi, James W. Murphy, Camille Keeler, David G. Myszka, Naomi E. Chayen, Elias J. Lolis & Michael E. Hodsdon. (2010) Two Independent Histidines, One in Human Prolactin and One in Its Receptor, Are Critical for pH-dependent Receptor Recognition and Activation. Journal of Biological Chemistry 285:49, pages 38524-38533.
Crossref
Crossref
Sivahari P. Gorantla, Tobias N. Dechow, Rebekka Grundler, Anna Lena Illert, Christian Meyer zum Büschenfelde, Marcus Kremer, Christian Peschel & Justus Duyster. (2010) Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice. Blood 116:22, pages 4600-4611.
Crossref
Crossref
Hsin-Yi WuVincent S. TsengLien-Chin ChenHui-Yin ChangI-Chi ChuangYeou-Guang TsayPao-Chi Liao. (2010) Identification of Tyrosine-Phosphorylated Proteins Associated with Lung Cancer Metastasis using Label-Free Quantitative Analyses. Journal of Proteome Research 9:8, pages 4102-4112.
Crossref
Crossref
Lawrence S. Argetsinger, Jeanne A. Stuckey, Scott A. Robertson, Rositsa I. Koleva, Joel M. Cline, Jarrod A. Marto, Martin G. MyersJr.Jr. & Christin Carter-Su. (2010) Tyrosines 868, 966, and 972 in the Kinase Domain of JAK2 Are Autophosphorylated and Required for Maximal JAK2 Kinase Activity. Molecular Endocrinology 24:5, pages 1062-1076.
Crossref
Crossref
Elisabeth R. Barton. (2010) Restoration of γ-Sarcoglycan Localization and Mechanical Signal Transduction Are Independent in Murine Skeletal Muscle. Journal of Biological Chemistry 285:22, pages 17263-17270.
Crossref
Crossref
Lequn ZhaoYue MaJoachim SeemannLily Jun-shen Huang. (2010) A regulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F). Biochemical Journal 426:1, pages 91-98.
Crossref
Crossref
Benjamin G. Neel, Gordon Chan & Salim Dhanji. 2010. Handbook of Cell Signaling. Handbook of Cell Signaling
771
809
.
Mojib Javadi Javed, Terri D. Richmond & Dwayne L. Barber. 2010. Handbook of Cell Signaling. Handbook of Cell Signaling
451
466
.
Chris Soon Heng Tan & Rune Linding. (2009) Experimental and computational tools useful for (re)construction of dynamic kinaseâsubstrate networks. PROTEOMICS 9:23, pages 5233-5242.
Crossref
Crossref
Lequn Zhao, Hongyun Dong, Cheng Cheng Zhang, Lisa Kinch, Mitsujiro Osawa, Michelina Iacovino, Nikolai V. Grishin, Michael Kyba & Lily Jun-shen Huang. (2009) A JAK2 Interdomain Linker Relays Epo Receptor Engagement Signals to Kinase Activation. Journal of Biological Chemistry 284:39, pages 26988-26998.
Crossref
Crossref
Brian R. Thompson, Anna M. Mazurkiewicz-Muñoz, Jill Suttles, Christin Carter-Su & David A. Bernlohr. (2009) Interaction of Adipocyte Fatty Acid-binding Protein (AFABP) and JAK2. Journal of Biological Chemistry 284:20, pages 13473-13480.
Crossref
Crossref
Celine C. Berthier, Hongyu Zhang, MaryLee Schin, Anna Henger, Robert G. Nelson, Berne Yee, Anissa Boucherot, Matthias A. Neusser, Clemens D. Cohen, Christin Carter-Su, Lawrence S. Argetsinger, Maria P. Rastaldi, Frank C. Brosius & Matthias Kretzler. (2009) Enhanced Expression of Janus Kinase–Signal Transducer and Activator of Transcription Pathway Members in Human Diabetic Nephropathy. Diabetes 58:2, pages 469-477.
Crossref
Crossref
Megumi Funakoshi-Tago, Kenji Tago, Tadashi Kasahara, Evan Parganas & James N. Ihle. (2008) Negative regulation of Jak2 by its auto-phosphorylation at tyrosine 913 via the Epo signaling pathway. Cellular Signalling 20:11, pages 1995-2001.
Crossref
Crossref
J Kota, N Caceres & S N Constantinescu. (2008) Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia 22:10, pages 1828-1840.
Crossref
Crossref
Issam McDoom, Xianyue Ma, Annet Kirabo, Kuang-Yung Lee, David A. Ostrov & Peter P. Sayeski. (2008) Identification of Tyrosine 972 as a Novel Site of Jak2 Tyrosine Kinase Phosphorylation and Its Role in Jak2 Activation. Biochemistry 47:32, pages 8326-8334.
Crossref
Crossref
Scott A. Robertson, Gina M. Leinninger & Martin G. MyersJr.Jr.. (2008) Molecular and neural mediators of leptin action. Physiology & Behavior 94:5, pages 637-642.
Crossref
Crossref
Martin G. MyersMichael A. CowleyHeike Münzberg. (2008) Mechanisms of Leptin Action and Leptin Resistance. Annual Review of Physiology 70:1, pages 537-556.
Crossref
Crossref
G. M. Leinninger & M. G. MyersJr.Jr.. (2007) LRb signals act within a distributed network of leptin-responsive neurones to mediate leptin action. Acta Physiologica 192:1, pages 49-59.
Crossref
Crossref
Rui Han, Beiling Chen & Terry J. Smith. (2007) Jak2 Dampens the Induction by IL-1β of Prostaglandin Endoperoxide H Synthase 2 Expression in Human Orbital Fibroblasts: Evidence for Divergent Influence on the Prostaglandin E2 Biosynthetic Pathway. The Journal of Immunology 179:10, pages 7147-7156.
Crossref
Crossref
Yolanda de Pablo, M. José Pérez-García, Maya V. Georgieva, Daniel Sanchis, Niclas Lindqvist, Rosa M. Soler, Joan X. Comella & Marta Llovera. (2007) Tyr-701 is a new regulatory site for neurotrophin receptor TrkA trafficking and function. Journal of Neurochemistry 0:0, pages 071115085713006-???.
Crossref
Crossref
Lulu Cao, Kebing Yu, Cindy Banh, Vinh Nguyen, Anna Ritz, Benjamin J. Raphael, Yuko Kawakami, Toshiaki Kawakami & Arthur R. Salomon. (2007) Quantitative Time-Resolved Phosphoproteomic Analysis of Mast Cell Signaling. The Journal of Immunology 179:9, pages 5864-5876.
Crossref
Crossref
Zhiqin Li, Yingjiang Zhou, Christin Carter-Su, Martin G. MyersJr.Jr. & Liangyou Rui. (2007) SH2B1 Enhances Leptin Signaling by Both Janus Kinase 2 Tyr813 Phosphorylation-Dependent and -Independent Mechanisms. Molecular Endocrinology 21:9, pages 2270-2281.
Crossref
Crossref
Ted H. Elsasser, Stanislaw Kahl, Cong-Jun Li, James L. Sartin, Wesley M. Garrett & José Rodrigo. (2007) Caveolae Nitration of Janus Kinase-2 at the 1007Y-1008Y Site: Coordinating Inflammatory Response and Metabolic Hormone Readjustment within the Somatotropic Axis. Endocrinology 148:8, pages 3803-3813.
Crossref
Crossref
Ted H. Elsasser, Cong-Jun Li, Thomas J. Caperna, Stanislaw Kahl & Walter F. Schmidt. (2007) Growth Hormone (GH)-Associated Nitration of Janus Kinase-2 at the 1007Y-1008Y Epitope Impedes Phosphorylation at This Site: Mechanism for and Impact of a GH, AKT, and Nitric Oxide Synthase Axis on GH Signal Transduction. Endocrinology 148:8, pages 3792-3802.
Crossref
Crossref
Young Lim Choi, Ruri Kaneda, Tomoaki Wada, Shin-ichiro Fujiwara, Manabu Soda, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita & Hiroyuki Mano. (2007) Identification of a constitutively active mutant of JAK3 by retroviral expression screening. Leukemia Research 31:2, pages 203-209.
Crossref
Crossref
Nathan J. Lanning & Christin Carter-Su. (2007) Recent advances in growth hormone signaling. Reviews in Endocrine and Metabolic Disorders 7:4, pages 225-235.
Crossref
Crossref
David J. Waxman & Caitlin O’Connor. (2006) Growth Hormone Regulation of Sex-Dependent Liver Gene Expression. Molecular Endocrinology 20:11, pages 2613-2629.
Crossref
Crossref
Victoria L. Grandage, Tamara Everington, David C. Linch & Asim Khwaja. (2006) Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. British Journal of Haematology 135:3, pages 303-316.
Crossref
Crossref
Megumi Funakoshi-Tago, Stephane Pelletier, Tadashi Matsuda, Evan Parganas & James N Ihle. (2006) Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2. The EMBO Journal 25:20, pages 4763-4772.
Crossref
Crossref
Asim Khwaja. (2006) The role of Janus kinases in haemopoiesis and haematological malignancy. British Journal of Haematology 134:4, pages 366-384.
Crossref
Crossref
Judith Staerk, Anders Kallin, Jean-Baptiste Demoulin, William Vainchenker & Stefan N. Constantinescu. (2005) JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation. Journal of Biological Chemistry 280:51, pages 41893-41899.
Crossref
Crossref
Kenneth Kaushansky. (2005) On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 105:11, pages 4187-4190.
Crossref
Crossref
Heike Münzberg & Martin G MyersJrJr. (2005) Molecular and anatomical determinants of central leptin resistance. Nature Neuroscience 8:5, pages 566-570.
Crossref
Crossref
Chloé James, Valérie Ugo, Jean-Pierre Le Couédic, Judith Staerk, François Delhommeau, Catherine Lacout, Loïc Garçon, Hana Raslova, Roland Berger, Annelise Bennaceur-Griscelli, Jean Luc Villeval, Stefan N. Constantinescu, Nicole Casadevall & William Vainchenker. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:7037, pages 1144-1148.
Crossref
Crossref
Terri D. Richmond, Manprit Chohan & Dwayne L. Barber. (2005) Turning cells red: signal transduction mediated by erythropoietin. Trends in Cell Biology 15:3, pages 146-155.
Crossref
Crossref
Kenneth Kaushansky. (2005) On the Molecular Origins of the Chronic Myeloproliferative Disorders: It All Makes Sense. Hematology 2005:1, pages 533-537.
Crossref
Crossref
William Vainchenker & Stefan N. Constantinescu. (2005) A Unique Activating Mutation in JAK2 (V617F) Is at the Origin of Polycythemia Vera and Allows a New Classification of Myeloproliferative Diseases. Hematology 2005:1, pages 195-200.
Crossref
Crossref
Tadashi Matsuda, Jian Feng, Bruce A. Witthuhn, Yuichi Sekine & James N. Ihle. (2004) Determination of the transphosphorylation sites of Jak2 kinase. Biochemical and Biophysical Research Communications 325:2, pages 586-594.
Crossref
Crossref